Últimas noticias sobre Biora Therapeutics (OTC:BIOR) Bolsa

Biora Therapeutics

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.

Biora Therapeutics Inc

BIORA THERAPEUTCS INC by Biora Therapeutics, Inc.

BioRegenx Inc

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

Biorem Inc

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics (BIOR – Research Report), with a pr...

Biora Therapeutics: Outperforming with Strong Q2 Financials and Clinical Advancements

Biora Therapeutics granted extension to regain compliance with Nasdaq

Biora Therapeutics stock falls as it looks to raise $3M via direct offering

Biora Therapeutics Q3 Earnings Preview

Here are the major earnings after the close today

Biora Therapeutics GAAP EPS of -$5.04 misses by $1.19, revenue of $0.03M

Biora Therapeutics ( ($BIOR) ) has issued an announcement. Biora Therapeutics faced potential delisting from Nasdaq due to failing to meet the mark...

Biora Therapeutics Faces Nasdaq Delisting Challenges

Biora Therapeutics (BIOR) has reached an agreement with certain of its prepetition creditors to provide financing to support a chapter 11 sale proc...

Biora Therapeutics undertakes Chapter 11 sales process

The latest update is out from Biora Therapeutics ( ($BIOR) ). Biora Therapeutics has filed for Chapter 11 bankruptcy to facilitate a sale process a...

Biora Therapeutics Files for Bankruptcy to Restructure

New option listings for December 31st include BIORA THERAPEUTICS INC (BIORQ). Option delistings effective December 31st include Biora Therapeutics ...

One new option listing and one option delisting on December 31st

AMAT

AQMS

AREC

ASND

ASTS

BIOR

BKKT

CNVS

CWCO

DARE

DESP

DNMR

GLOB

HYLN

IZEA

LCTX

LNVGY

OKLO

ORGN

POST

PPSI

PSTV

REKR

RSLS

SPRO

TTOO

VUZI

Markets

Press Releases

Biora Therapeutics Announces Positive Nasdaq Listing Decision

Biora Therapeutics Achieves ISO 13485 Certification

News

Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium

Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

Health Care

Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Financing

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Earnings

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth

HC Wainwright & Co.

Comments

Biora Therapeutics

Noticias

Últimas noticias sobre Biora Therapeutics (OTC:BIOR) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL